Co-Authors
This is a "connection" page, showing publications co-authored by EHAB Y HANNA and RENATA FERRAROTTO.
Connection Strength
3.959
-
Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma. Oral Oncol. 2024 Apr; 151:106759.
Score: 0.249
-
Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance. Mod Pathol. 2024 Jan; 37(1):100371.
Score: 0.242
-
Sinonasal NUT carcinoma: A consecutive case series and systematic review. Head Neck. 2024 Jan; 46(1):29-36.
Score: 0.241
-
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851.
Score: 0.231
-
Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg. 2023 08; 169(2):435-440.
Score: 0.231
-
Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol. 2023 03; 138:106311.
Score: 0.229
-
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022 02 01; 128(3):509-518.
Score: 0.210
-
Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature. Laryngoscope. 2022 02; 132(2):290-297.
Score: 0.207
-
Role of induction chemotherapy for oral cavity squamous cell carcinoma. Cancer. 2021 09 01; 127(17):3107-3112.
Score: 0.203
-
Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers. Head Neck. 2021 02; 43(2):613-621.
Score: 0.196
-
High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol. 2020 Dec; 49:151622.
Score: 0.195
-
Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020 02; 101:104523.
Score: 0.185
-
Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol. 2019 02 20; 37(6):504-512.
Score: 0.173
-
Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679.
Score: 0.155
-
Orbital and periocular complications in patients with sinonasal tumours with orbital invasion. Br J Ophthalmol. 2024 02 21; 108(3):465-470.
Score: 0.062
-
Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors. Head Neck. 2024 03; 46(3):627-635.
Score: 0.061
-
Visual outcome and ocular complications in patients with lacrimal gland carcinoma after eye-sparing surgery and adjuvant radiation therapy. Br J Ophthalmol. 2023 11 22; 107(12):1914-1919.
Score: 0.061
-
Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Curr Oncol Rep. 2023 01; 25(1):1-10.
Score: 0.057
-
Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther. 2021; 8(1):108-118.
Score: 0.051
-
Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. Int J Part Ther. 2021; 8(1):261-272.
Score: 0.051
-
The tumor immune contexture of salivary duct carcinoma. Head Neck. 2021 04; 43(4):1213-1219.
Score: 0.050
-
Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation. Cancer. 2021 02 15; 127(4):528-534.
Score: 0.049
-
Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope. 2021 05; 131(5):E1468-E1475.
Score: 0.049
-
Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020 06; 42(6):1194-1201.
Score: 0.048
-
Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. Radiother Oncol. 2020 07; 148:258-266.
Score: 0.048
-
Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. Head Neck. 2020 06; 42(6):1179-1186.
Score: 0.048
-
A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck. 2020 03; 42(3):485-497.
Score: 0.046
-
Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head Neck. 2019 11; 41(11):4036-4050.
Score: 0.045
-
Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base. 2020 Dec; 81(6):638-644.
Score: 0.045
-
Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope. 2020 01; 130(1):86-93.
Score: 0.044
-
Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. Head Neck. 2018 12; 40(12):2596-2605.
Score: 0.043
-
Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope. 2018 06; 128(6):1274-1280.
Score: 0.040
-
Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 11 23; 12(1):186.
Score: 0.040
-
Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
Score: 0.040
-
Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther. 2015; 16(6):834-8.
Score: 0.034